Pfizer Working To Resolve Sickle Cell Drug Hold Up, Dolsten Says

Rivipansel, partnered with GlycoMimetics, is one of the most advanced drugs in Pfizer’s rare disease pipeline. Phase III studies have been delayed, however, due to a manufacturing issue impacting supply.

The start of Phase III clinical trials for Pfizer Inc./GlycoMimetics Inc.’s rivipansel for vaso-occlusive crisis (VOC) of sickle cell disease will be delayed at least six months and possibly a year due to a manufacturing development issue that Pfizer is working to resolve.

Rivipansel is one of the most advanced drugs in Pfizer’s rare disease pipeline, a portfolio the company highlighted during a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Pink Sheet